Search / 1 result found

from
to
  • Updated

CARY, N.C., April 30, 2021 /PRNewswire/ -- Phoenix Cardiac Devices, Inc., an innovator in cardiovascular medical device research and development, today presented pivotal data for its BACE™ (Basal Annuloplasty of the Cardia Externally) device, a novel modality for the treatment of Functional Mitral Regurgitation (FMR), at the virtual American Association for Thoracic Surgery (AATS) 101st annual meeting. In a late-breaking presentation, researchers reported positive outcomes including a reduction in the degree of FMR and stabilization of left ventricular function in patients undergoing external cardiac support with the BACE device.1 The data are the basis of a CE Mark that Phoenix Cardiac recently received for the BACE device, allowing it to be sold on the European market.